Added to YB: 2026-08-31
Pitch date: 2026-08-27
EXOZ [bullish]
eXoZymes, Inc.
+2.25%
current return
Author Info
Slack Capital is an investment publication dedicated to sharing only a select few opportunities each year. Through 12 years of investing, I have found that deep research and a focused concentration have consistently outperformed a broad, generalised approach. By making informed, strategic investments, I have been able to generate significant returns while consistently strengthening my confidence in my allocation decisions. At the core of Slack Capital's publication are the offered investment reports, often the result of over 50 hours of research, where all available information on a company is meticulously compiled and filtered into a centralised analysis. Sign up for the newsletter.
Company Info
eXoZymes, Inc. operates as a development stage biotechnology company. It focuses on the development of enzyme modules and cell-free exozyme biosolutions for synthetic biology manufacturing.
Market Cap
$69.8M
Pitch Price
$7.01
Price Target
N/A
Dividend
N/A
EV/EBITDA
-6.60
P/E
-6.26
EV/Sales
N/A
Sector
Biotechnology
Category
growth
Inside eXoZymes’ Strategic Shift: Building a Compounding Value Flywheel
EXOZ (update): eXoZymes is shifting from early research partnerships to retaining internally selected molecules through key milestones, aiming to capture better economics from a repeatable asset-development flywheel. Lead program NCT OTC has reached a third-party-operated 100-litre pilot, with subsequent optimisations lifting productivity about 10x and cutting estimated manufacturing cost by more than 100x. Manufacturing and commercial-partner selections are targeted for Q3 and Q4 2026, but the pre-revenue strategy raises near-term capital needs.
Read full article (9 min)